| 形态 | Liquid |
|---|
| 宿主种属 | Humanized |
|---|
| 克隆性 | Monoclonal |
|---|
| 抗体亚型 | IgG4-kappa |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| 浓度 | 1mg/ml |
|---|
| 内毒素水平 | Please contact the lab for this information. |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 种属反应性 | Human |
|---|
| 靶标 | Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279 |
|---|
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
|---|
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| 表达系统 | Mammalian Cells |
|---|
| 登录号 | Q15116 |
|---|
| 背景信息 | Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.<br>• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870<br/>• PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations., PMID:30888929<br/>• The diverse functions of the PD1 inhibitory pathway., PMID:28990585<br/>• PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy., PMID:30191996<br/>• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845<br/>• PD-1 expression and clinical PD-1 blockade in B-cell lymphomas., PMID:29118007<br/>• Overcoming T cell exhaustion in infection and cancer., PMID:25797516<br/>• Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker., PMID:32875727<br/>• Tumor Mutational Burden and Response Rate to PD-1 Inhibition., PMID:29262275<br/>• PD-L1., PMID:29097600<br/> |
|---|
| 别名 | HLX10, 2231029-82-4 |
|---|
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
|---|